Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 480 INR Market Closed
Market Cap: 1.2T INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CIPLA stock under the Base Case scenario is 1 533.35 INR. Compared to the current market price of 1 480 INR, Cipla Ltd is Undervalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CIPLA Relative Value
Base Case
1 533.35 INR
Undervaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.4
P/S
P/S
Price to Sales
4.4
vs History
17
vs Industry
27
Median 3Y
4.1
Median 5Y
3.8
Industry
2.4
Forward
4.2
More Details
24
P/E
P/E
Price to Earnings
24
vs History
92
vs Industry
19
Median 3Y
28.4
Median 5Y
29.5
Industry
20.3
Forward
23.8
More Details
26.6
P/OCF
P/OCF
Price to OCF
26.6
vs History
31
vs Industry
15
Median 3Y
27.4
Median 5Y
24.5
Industry
15.6
More Details
50.9
P/FCFE
P/FCFE
Price to FCFE
50.9
vs History
55
vs Industry
11
Median 3Y
52.7
Median 5Y
52.7
Industry
23.1
More Details
4.2
P/B
P/B
Price to Book Value
4.2
vs History
25
vs Industry
17
Median 3Y
4.1
Median 5Y
3.9
Industry
2
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
17
vs Industry
29
Median 3Y
3.9
Median 5Y
3.6
Industry
2.5
Forward
3.9
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
31
vs Industry
33
Median 3Y
6.1
Median 5Y
5.8
Industry
4.8
More Details
16.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.2
vs History
50
vs Industry
22
Median 3Y
16.7
Median 5Y
16.3
Industry
12.5
Forward
15.1
More Details
19.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19.1
vs History
82
vs Industry
22
Median 3Y
20.8
Median 5Y
20.9
Industry
15.7
Forward
17.7
More Details
24.7
EV/OCF
EV/OCF
Enterprise Value to OCF
24.7
vs History
31
vs Industry
17
Median 3Y
25.4
Median 5Y
23.1
Industry
14.1
More Details
37.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
37.7
vs History
30
vs Industry
13
Median 3Y
37.8
Median 5Y
32.5
Industry
17.6
More Details
4.8
EV/IC
EV/IC
Enterprise Value to IC
4.8
vs History
20
vs Industry
16
Median 3Y
4.4
Median 5Y
3.9
Industry
1.8
More Details

Multiples Across Competitors

CIPLA Competitors Multiples
Cipla Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Cipla Ltd
NSE:CIPLA
1.2T INR 4.4 24 16.2 19.1
US
Eli Lilly and Co
NYSE:LLY
715.5B USD 14.6 64.6 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375B USD 4.2 17.1 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.6
CH
Roche Holding AG
SIX:ROG
203.2B CHF 3.4 24.7 9.2 10.8
CH
Novartis AG
SIX:NOVN
177.8B CHF 4 16.6 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.9B GBP 3.8 27.1 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
197.6B USD 3.1 11.3 8.2 9.8
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.3B EUR 1.3 9.2 5 5.9
P/E Multiple
Earnings Growth PEG
IN
Cipla Ltd
NSE:CIPLA
Average P/E: 23.8
24
10%
2.4
US
Eli Lilly and Co
NYSE:LLY
64.6
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.7
32%
0.8
CH
Novartis AG
SIX:NOVN
16.6
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Cipla Ltd
NSE:CIPLA
Average EV/EBITDA: 395.1
16.2
7%
2.3
US
Eli Lilly and Co
NYSE:LLY
34.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.2
6%
1.5
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Cipla Ltd
NSE:CIPLA
Average EV/EBIT: 1 698.4
19.1
7%
2.7
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
9.8
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
CIPLA intrinsic value, competitors valuation, and company profile.
DCF Valuation
CIPLA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CIPLA stock valuation using valuation multiples.
Wall Street Estimates
CIPLA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CIPLA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.